High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma.

ABSTRACT: Multiple myeloma (MM) is a genetically heterogeneous malignancy characterized by variable treatment responses. Although numerous drugs have been approved in recent years, the ability to predict treatment response and tailor individual therapy is limited by the absence of robust predictive biomarkers. The goal of this clinical trial was to use ex vivo, high-throughput screening (HTS) of 170 compounds to predict response among patients with relapsed or refractory MM and inform the next treatment decisions. Additionally, we integrated HTS with multi-omic analysis to uncover novel associations between in vitro drug sensitivity and gene expression and mutation profiles.

Materials and methods

Twenty-five patients with relapsed or refractory MM underwent a screening bone marrow or soft tis

SUBMITTER: Coffey DG 

PROVIDER: S-EPMC8232547 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature